156 related articles for article (PubMed ID: 30641835)
1. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma.
Chen CH; Chen PY; Lin YY; Feng LY; Chen SH; Chen CY; Huang YC; Huang CY; Jung SM; Chen LY; Wei KC
J Neurosurg; 2019 Jan; 132(1):168-179. PubMed ID: 30641835
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3).
Yang CH; Yue J; Pfeffer SR; Fan M; Paulus E; Hosni-Ahmed A; Sims M; Qayyum S; Davidoff AM; Handorf CR; Pfeffer LM
J Biol Chem; 2014 Sep; 289(36):25079-87. PubMed ID: 25059666
[TBL] [Abstract][Full Text] [Related]
3. SiRNA-mediated knockdown against NUF2 suppresses tumor growth and induces cell apoptosis in human glioma cells.
Huang SK; Qian JX; Yuan BQ; Lin YY; Ye ZX; Huang SS
Cell Mol Biol (Noisy-le-grand); 2014 Nov; 60(4):30-6. PubMed ID: 25481014
[TBL] [Abstract][Full Text] [Related]
4. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
[TBL] [Abstract][Full Text] [Related]
5. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
[TBL] [Abstract][Full Text] [Related]
6. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.
Gillespie DL; Aguirre MT; Ravichandran S; Leishman LL; Berrondo C; Gamboa JT; Wang L; King R; Wang X; Tan M; Malamas A; Lu ZR; Jensen RL
J Neurosurg; 2015 Feb; 122(2):331-41. PubMed ID: 25423275
[TBL] [Abstract][Full Text] [Related]
7. Combination gene therapy with PTEN and EGFR siRNA suppresses U251 malignant glioma cell growth in vitro and in vivo.
Han L; Zhang AL; Xu P; Yue X; Yang Y; Wang GX; Jia ZF; Pu PY; Kang CS
Med Oncol; 2010 Sep; 27(3):843-52. PubMed ID: 19728186
[TBL] [Abstract][Full Text] [Related]
8. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
9. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
Fukunaga T; Fujita Y; Kishima H; Yamashita T
PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142
[TBL] [Abstract][Full Text] [Related]
10. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R.
Guo T; Feng Y; Liu Q; Yang X; Jiang T; Chen Y; Zhang Q
Tumour Biol; 2014 Nov; 35(11):11269-75. PubMed ID: 25117070
[TBL] [Abstract][Full Text] [Related]
12. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
14. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
15. (Pro)renin receptor is crucial for glioma development via the Wnt/β-catenin signaling pathway.
Kouchi M; Shibayama Y; Ogawa D; Miyake K; Nishiyama A; Tamiya T
J Neurosurg; 2017 Oct; 127(4):819-828. PubMed ID: 28059652
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD146 using folic acid-conjugated nanoparticles and suppression of tumor growth in a mouse glioma model.
Fukui N; Yawata T; Nakajo T; Kawanishi Y; Higashi Y; Yamashita T; Aratake T; Honke K; Ueba T
J Neurosurg; 2020 Jul; 134(6):1772-1782. PubMed ID: 32707539
[TBL] [Abstract][Full Text] [Related]
17. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
18. Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
Higgins DMO; Caliva M; Schroeder M; Carlson B; Upadhyayula PS; Milligan BD; Cheshier SH; Weissman IL; Sarkaria JN; Meyer FB; Henley JR
BMC Cancer; 2020 Dec; 20(1):1213. PubMed ID: 33302912
[TBL] [Abstract][Full Text] [Related]
19. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.
Shankavaram UT; Bredel M; Burgan WE; Carter D; Tofilon P; Camphausen K
J Cell Mol Med; 2012 Mar; 16(3):545-54. PubMed ID: 21595825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
